G1 Therapeutics Q2 2024 GAAP EPS $(0.10) Beats $(0.17) Estimate, Sales $16.546M Beat $16.363M Estimate
Portfolio Pulse from Benzinga Newsdesk
G1 Therapeutics (NASDAQ:GTHX) reported Q2 2024 GAAP EPS of $(0.10), beating the $(0.17) estimate. Sales were $16.546M, surpassing the $16.363M estimate. Despite beating estimates, both EPS and sales saw significant declines compared to the same period last year.
August 08, 2024 | 10:33 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
G1 Therapeutics reported better-than-expected Q2 2024 GAAP EPS and sales, but both metrics saw significant declines compared to the same period last year.
While G1 Therapeutics beat analyst estimates for both EPS and sales, the significant year-over-year declines in both metrics may temper investor enthusiasm. The mixed results could lead to neutral short-term price movement.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100